Becker Capital Management Inc. Has $57.82 Million Holdings in Gilead Sciences, Inc. (GILD)

Becker Capital Management Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 748,858 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the period. Gilead Sciences accounts for 1.8% of Becker Capital Management Inc.’s portfolio, making the stock its 11th largest position. Becker Capital Management Inc. owned 0.06% of Gilead Sciences worth $57,819,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its position in Gilead Sciences by 5.3% in the first quarter. Principal Financial Group Inc. now owns 2,945,595 shares of the biopharmaceutical company’s stock valued at $222,068,000 after buying an additional 148,398 shares during the last quarter. Fisher Asset Management LLC boosted its position in Gilead Sciences by 5.9% in the second quarter. Fisher Asset Management LLC now owns 559,568 shares of the biopharmaceutical company’s stock valued at $39,640,000 after buying an additional 31,109 shares during the last quarter. Xact Kapitalforvaltning AB boosted its position in Gilead Sciences by 1.2% in the second quarter. Xact Kapitalforvaltning AB now owns 264,883 shares of the biopharmaceutical company’s stock valued at $18,764,000 after buying an additional 3,057 shares during the last quarter. Addenda Capital Inc. boosted its position in Gilead Sciences by 91.5% in the second quarter. Addenda Capital Inc. now owns 155,142 shares of the biopharmaceutical company’s stock valued at $11,357,000 after buying an additional 74,123 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its position in Gilead Sciences by 2.0% in the second quarter. NN Investment Partners Holdings N.V. now owns 942,209 shares of the biopharmaceutical company’s stock valued at $66,748,000 after buying an additional 18,385 shares during the last quarter. 78.09% of the stock is owned by hedge funds and other institutional investors.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total value of $3,708,000.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $227,505,229.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 150,000 shares of company stock valued at $11,087,500 over the last three months. 1.30% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently commented on the company. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday. Mizuho set a $94.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Friday, October 26th. Barclays upped their target price on Gilead Sciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 26th. Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, October 31st. Finally, Robert W. Baird lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a research report on Thursday, July 26th. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $87.84.

Shares of NASDAQ:GILD opened at $71.18 on Friday. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54. The company has a market capitalization of $91.20 billion, a price-to-earnings ratio of 8.32, a P/E/G ratio of -2.73 and a beta of 1.01. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.47 and a quick ratio of 3.39.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the previous year, the company posted $2.27 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.44 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s payout ratio is presently 26.64%.

COPYRIGHT VIOLATION NOTICE: “Becker Capital Management Inc. Has $57.82 Million Holdings in Gilead Sciences, Inc. (GILD)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/11/10/becker-capital-management-inc-has-57-82-million-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Read More: Outstanding Shares, Buying and Selling Stocks

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply